Biopharma companies raised $2.98 billion through 59 transactions in February 2025, down from $5.91 billion across 93 deals in January. The year is off to a slower start compared to 2023, with the $9.14 billion raised in the first two months, marking a 73% drop from $33.29 billion during the same period last year. However, this year's total is higher than the $7.66 billion raised in the first two months of 2023 and the $7.48 billion in 2022.

Med-tech companies raised $3.52 billion in 65 deals in February 2025, up from $2.76 billion across 56 transactions in January.

The BioWorld Neurological Diseases Index closed 2024 down 20.27%, extending its decline from -13.4% at the end of November. After falling to -12.2% in April, the index briefly rebounded, narrowing losses to under 4% by June, before experiencing a sharp downturn in the second half of the year.

Biopharma companies raised $2.98 billion through 59 transactions in February 2025, down from $5.91 billion across 93 deals in January. The year is off to a slower start compared to 2023, with the $9.14 billion raised in the first two months, marking a 73% drop from $33.29 billion during the same period last year. However, this year's total is higher than the $7.66 billion raised in the first two months of 2023 and the $7.48 billion in 2022.

In January 2025, BioWorld tracked 171 phase I-III clinical trial updates, down from 212 in December. The month delivered 12 successful phase III outcomes, six of those in cancer, while two trials ended in failure.

The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it remained in positive territory through November, up 3.58%, the steady decline through the later months of the year pushed the index into the red by December’s close.

The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.

Despite the number of med-tech deals increasing to 1,902 in 2024, up 12% from 1,701 in 2023, the value of these deals has dramatically declined compared to previous years.

The BioWorld Infectious Disease Index (BIDI) faced challenges throughout the year but narrowed its losses, ending down 6.28% after hitting a low of -25.12% in late April. By October, the index was down 12.07% and had declined 8.86% for the year as of Nov. 22. However, in January, the BIDI rebounded slightly, gaining 1.85%.

The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.